ABC | Volume 111, Nº3, Setembro 2018

Diretrizes Diretriz Brasileira de Insuficiência Cardíaca Crônica e Aguda Arq Bras Cardiol. 2018; 111(3):436-539 547. Kaufman R, Azevdeo MM, Xavier RM, Gelle M, Chaves R, Castier M. Evolution of heart failure-related hospital admissions andmortality-rates. Int J Cardiovasc Sci. 2015;28(4):276-81. 548. Torosoff M, Sader C, Philbin E. Congestive heart failure. In: Weintraub W. (editor). Cardiovascular healthcare economics. New Jersey: Humana Press; 2009. p. 529-84. 549. Mejhert M, Lindgren P, Schill O, Edner M, Persson H, Kahan T. Long term health care consumption and cost expenditure in systolic heart failure. Eur J Intern Med. 2013;24(3):260-5. 550. Weintraub SW, Cole J, Tooley JF. Cost and cost-effectiveness studies in heart failure research. AmHeart J. 2002;143(4):565-76. 551. Rohde LE, Bertoldi EG, Goldraich L, Polanczyk CA. Cost-effectiveness of heart failure therapies. Nat Rev Cardiol. 2013;10(6):338-54. 552. LeeD,WilsonK,AkehurstR,CowieMR,ZannadF,KrumH,etal;Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure (EMPHASIS-HF) Study. Cost-effectiveness of eplerenone in patients with systolic heart failure andmild symptoms. Heart. 2014;100(21):1681-7. 553. Ademi Z, Pasupathi K, KrumH, LiewD. Cost effectiveness of eplerenone in patients with chronic heart failure. Am J Cardiovasc Drugs. 2014;14(3):209-16. 554. McKenna C, Walker S, Lorgelly P, Fenwick E, Burch J, Suekarran S, et al. Cost-effectiveness of aldosterone antagonists for the treatment of post- myocardial infarction heart failure. Value Health. 2012;15(3):420-8. 555. Griffiths A, Paracha N, Davies A, Branscombe N, Cowie MR, Sculpher M. The cost effectiveness of ivabradine in the treatment of chronic heart failure from the UK National Health Service perspective. Heart. 2014;100(13):1031-6. 556. Kourlaba G, Parissis J, Karavidas A, Beletsi A, Milonas C, Branscombe N, et al. Economic evaluation of ivabradine in the treatment of chronic heart failure in Greece. BMC Health Serv Res. 2014 Dec 11;14:631-40. 557. Ramos IC, VersteeghMM, de Boer RA, Koenders JM, LinssenGC, Meeder JG, et al. Cost Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic Guidelines. Value Health. 2017;20(10):1260-9. 558. van der Pol S, Degener F, Postma MJ, Vemer P. An Economic Evaluation of Sacubitril/Valsartan for Heart Failure Patients in the Netherlands. Value Health. 2017;20(3):388-96. 559. Sandhu AT, Ollendorf DA, Chapman RH, Pearson SD, Heidenreich PA. Cost-effectiveness of sacubitril-valsartan in patients who have heart failure with reduced ejection fraction. Ann Intern Med. 2017;166(8):607-8. 560. Mcmurray JJ, TruemanD, Hancock E, CowieMR, Briggs A, Taylor M, et al. Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction. Heart. 2018;104(12):1006-13. 561. Mejía A, Richardson G, Pattenden J, Cockayne S, Lewin R. Cost- effectiveness of a nurse facilitated, cognitive behavioural self-management programme compared with usual care using a CBT manual alone for patients with heart failure: secondary analysis of data from the SEMAPHFOR trial. Int J Nurs Stud. 2014;51(9):1214-20. 562. Maru S, Byrnes J, CarringtonMJ, Chan YK, ThompsonDR, Stewart S, et al; WHICH?Trial Investigators.Cost-effectivenessofhomeversusclinic-based management of chronic heart failure: extended follow-up of a pragmatic, multicentre randomized trial cohort—TheWHICH? study (WhichHeart Failure Intervention Is Most Cost-Effective and Consumer Friendly in Reducing Hospital Care). Int J Cardiol. 2015 Dec 15;201:368-75. 563. BocchiEA,daCruzFD,BrandãoSM,IssaV,Ayub-FerreiraSM,laRoccaHB,etal. Cost-effectivenessbenefitsofadiseasemanagementprogram:theREMADHE TrialResults.JCardFail.2018Apr30.pii:S1071-9164(18)30168-4. 564. DangW, Yi A, Jhamnani S,Wang SY. Cost-effectiveness of multidisciplinary management program and exercise training program in heart failure. Am J Cardiol. 2017;120(8):1338-43. 565. Kühr EM, Ribeiro RA, Rohde LE, Polanczyk CA. Cost-effectiveness of supervised exercise therapy in heart failure patients. Value Health 2011;4(5 Suppl 1): S100-7. 566. Boyne JJ, Van Asselt AD, Gorgels AP, Steuten LM, De Weerd G, Kragten J, et al. Cost-effectiveness analysis of telemonitoring versus usual care in patients with heart failure: The TEHAF–study. J Telemed Telecare. 2013;19(5):242-8. 567. Cano Martín JA, Martínez-Pérez B, de la Torre-Díez I, López-Coronado M. Economic impact assessment from the use of amobile app for the self- management of heart diseases by patients with heart failure in a Spanish region. J Med Syst. 2014;38(9):96. 568. Neumann A, Mostardt S, Biermann J, GelbrichG, Goehler A, Geisler BP, et al. Cost-effectiveness and cost-utility of a structured collaborative disease management inthe InterdisciplinaryNetwork forHeartFailure (INH)study. Clin Res Cardiol. 2015;104(4):304-9. 569. Hutchinson J, Scott DA, Clegg AJ, Loveman E, Royle P, Bryant J, et al. Cost- effectiveness of left ventricular-assist devices in end-stage heart failure. Expert Rev Cardiovasc Ther. 2008;6(2):175-85. 570. Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2017 Update: a report from the American Heart Association. Circulation. 2017;135(10):e146-e603. 571. Gheorghiade M, Shah AN, Vaduganathan M, Butler J, Bonow RO, Rosano GM, et al. Recognizing hospitalized heart failure as an entity and developing new therapies to improve outcomes: academics', clinicians', industry's, regulators', and payers' perspectives. Heart Fail Clin. 2013;9(3):285-90, v-vi. 572. Maggioni AP, Dahlström U, Filippatos G, Chioncel O, Crespo Leiro M, Drozdz J, et al; Heart Failure Association of the European Society of Cardiology (HFA). EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail. 2013;15(7):808-17. 573. Brasil. Ministério da Saúde. Datasus. Internações por insuficiência cardíaca. Brasília; 2017. 574. Kociol RD, Hammill BG, Fonarow GC, Klaskala W, Mills RM, Hernandez AF, et al. Generalizability and longitudinal outcomes of a national heart failure clinical registry: Comparison of Acute Decompensated Heart Failure National Registry (ADHERE) and non-ADHERE Medicare beneficiaries. AmHeart J. 2010;160(5):885-92. 575. Metra M, Felker GM, Zacà V, Bugatti S, Lombardi C, Bettari L, et al. Acute heart failure: multiple clinical profiles and mechanisms require tailored therapy. Int J Cardiol. 2010;144(2):175-9. 576. Filippatos G, Zannad F. An introduction to acute heart failure syndromes: definition and classification. Heart Fail Rev. 2007;12(2):87-90. 577. Mebazaa A, Yilmaz MB, Levy P, Ponikowski P, Peacock WF, Laribi S, et al. Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. Eur J Heart Fail. 2015;17(6):544-58. 578. Wuerz RC, Meador SA. Effects of prehospital medications on mortality and length of stay in congestive heart failure. Ann Emerg Med. 1992;21(6):669-74. 579. PeacockWF, Emerman C, CostanzoMR, Diercks DB, LopatinM, Fonarow GC. Early vasoactive drugs improve heart failure outcomes. Congest Heart Fail. 2009;15(6):256-64. 580. Ducros L, Logeart D, Vicaut E, Henry P, Plaisance P, Collet JP, et al; CPAP collaborative study group. CPAP for acute cardiogenic pulmonary oedema from out-of-hospital to cardiac intensive care unit: a randomised multicentre study. Intensive Care Med. 2011;37(9):1501-9. 533